Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors
Purpose To assess the safety and effectiveness of transarterial chemoembolization (TACE) of patients who have hepatocellular carcinomas (HCCs) with central bile duct invasion. Materials and Methods The institutional review board approved this retrospective study and waived informed consent. Fifty-th...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular and interventional radiology 2015-08, Vol.38 (4), p.937-945 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 945 |
|---|---|
| container_issue | 4 |
| container_start_page | 937 |
| container_title | Cardiovascular and interventional radiology |
| container_volume | 38 |
| creator | Choi, Jin Woo Chung, Jin Wook Cho, Yun Ku Kim, Yoon Jun Yoon, Jung-Hwan Kim, Hyo-Cheol Jae, Hwan Jun |
| description | Purpose
To assess the safety and effectiveness of transarterial chemoembolization (TACE) of patients who have hepatocellular carcinomas (HCCs) with central bile duct invasion.
Materials and Methods
The institutional review board approved this retrospective study and waived informed consent. Fifty-three patients, initially treated with TACE for HCCs with central bile duct invasion from January 1999 to September 2012, were included. Clinical, laboratory, and survival data were reviewed. Complications and hospitalization length were evaluated using the
χ
2
test, Fisher’s exact test, and logistic regression analysis. Survival was analyzed using the Kaplan–Meier method with log-rank test and Cox proportional hazard model.
Results
Seven patients experienced TACE-related major complications (severe post-embolization syndrome in 3, non-fatal sepsis in 3, and secondary bacterial peritonitis in 1). The overall major complication rate was 13.2 %, but there were no permanent adverse sequelae or deaths within 30 days. Serum total bilirubin ≥3.0 mg/dL was the only significant risk factor for long hospitalization [hazard ratio (HR) = 4.341,
p
= .022]. The median survival was 12.2 months. Extrahepatic metastasis (HR = 6.145,
p
|
| doi_str_mv | 10.1007/s00270-014-1032-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22469874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3742045661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-9f323e551ab620fd51bd31042bff821b00e9c59f7f66e7b8bf06c64e8d449fb83</originalsourceid><addsrcrecordid>eNp1kcFu1TAQRS0Eoq-FD2CDLLFh0YDt2E7CDlJKK1UCiSKxsxxn3OcqsV9tp6h8AZ-Nn1IKG1Yea869o5mL0AtK3lBCmreJENaQilBeUVKzqnuENpSXgrTy-2O0IbQpHSHoATpM6ZoQKlomnqIDJrgURIoN-nUZtU86ZohOT7jfwhxgHsLkfursgsc2RHwGO52DgWlaJh1xr6NxPsw64R8ub3EPPsci_uAmwCeLyfjc3-pU1O_wV20h3x3jLzFc-ZBcOsbaj-ULozPZ3QI-1SaHmJ6hJ1ZPCZ7fv0fo2-nHy_6suvj86bx_f1EZ3pBcdbZmNZSV9CAZsaOgw1hTwtlgbcvoQAh0RnS2sVJCM7SDJdJIDu3IeWeHtj5Cr1bfkLJTybgMZmuC92CyYozLrm14oV6v1C6GmwVSVrNL-wNoD2FJispOypZx0f01fECvwxJ92WFPiU7UvG0KRVfKxJBSBKt20c063ilK1D5MtYapSphqH6baO7-8d16GGcYHxZ_0CsBWIJWWv4L4z-j_uv4GZrqqvQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695953487</pqid></control><display><type>article</type><title>Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><creator>Choi, Jin Woo ; Chung, Jin Wook ; Cho, Yun Ku ; Kim, Yoon Jun ; Yoon, Jung-Hwan ; Kim, Hyo-Cheol ; Jae, Hwan Jun</creator><creatorcontrib>Choi, Jin Woo ; Chung, Jin Wook ; Cho, Yun Ku ; Kim, Yoon Jun ; Yoon, Jung-Hwan ; Kim, Hyo-Cheol ; Jae, Hwan Jun</creatorcontrib><description>Purpose
To assess the safety and effectiveness of transarterial chemoembolization (TACE) of patients who have hepatocellular carcinomas (HCCs) with central bile duct invasion.
Materials and Methods
The institutional review board approved this retrospective study and waived informed consent. Fifty-three patients, initially treated with TACE for HCCs with central bile duct invasion from January 1999 to September 2012, were included. Clinical, laboratory, and survival data were reviewed. Complications and hospitalization length were evaluated using the
χ
2
test, Fisher’s exact test, and logistic regression analysis. Survival was analyzed using the Kaplan–Meier method with log-rank test and Cox proportional hazard model.
Results
Seven patients experienced TACE-related major complications (severe post-embolization syndrome in 3, non-fatal sepsis in 3, and secondary bacterial peritonitis in 1). The overall major complication rate was 13.2 %, but there were no permanent adverse sequelae or deaths within 30 days. Serum total bilirubin ≥3.0 mg/dL was the only significant risk factor for long hospitalization [hazard ratio (HR) = 4.341,
p
= .022]. The median survival was 12.2 months. Extrahepatic metastasis (HR = 6.145,
p
< .001), international normalized ratio (PT-INR) ≥1.20 (HR = 4.564,
p
< .001), vascular invasion (HR = 3.484,
p
= .001), and intermediate tumor enhancement (HR = 2.417,
p
= .019) were significantly associated with shorter survival.
Conclusion
TACE can be a safe and effective treatment for patients who have HCCs with central bile duct invasion. In particular, long-term survival can be expected if patients have strongly enhancing tumors without poor prognostic factors such as extrahepatic metastasis, PT-INR prolongation, and vascular invasion.</description><identifier>ISSN: 0174-1551</identifier><identifier>EISSN: 1432-086X</identifier><identifier>DOI: 10.1007/s00270-014-1032-9</identifier><identifier>PMID: 25465065</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Bile Ducts - pathology ; BILIARY TRACT ; BILIRUBIN ; Carcinoma, Hepatocellular - diagnostic imaging ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Cardiology ; Chemoembolization, Therapeutic ; Clinical Investigation ; DEATH ; Female ; HAZARDS ; HEPATOMAS ; Humans ; Imaging ; Kaplan-Meier Estimate ; Length of Stay - statistics & numerical data ; Liver Neoplasms - diagnostic imaging ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Male ; Medicine ; Medicine & Public Health ; METASTASES ; Middle Aged ; Neoplasm Invasiveness ; Nuclear Medicine ; PATIENTS ; PERITONITIS ; Prognosis ; Proportional Hazards Models ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; REGRESSION ANALYSIS ; Retrospective Studies ; REVIEWS ; Survival Rate ; Tomography, X-Ray Computed ; Treatment Outcome ; Ultrasound ; VASCULAR DISEASES ; WHO</subject><ispartof>Cardiovascular and interventional radiology, 2015-08, Vol.38 (4), p.937-945</ispartof><rights>Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2014</rights><rights>Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-9f323e551ab620fd51bd31042bff821b00e9c59f7f66e7b8bf06c64e8d449fb83</citedby><cites>FETCH-LOGICAL-c470t-9f323e551ab620fd51bd31042bff821b00e9c59f7f66e7b8bf06c64e8d449fb83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00270-014-1032-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00270-014-1032-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,315,781,785,886,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25465065$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22469874$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Jin Woo</creatorcontrib><creatorcontrib>Chung, Jin Wook</creatorcontrib><creatorcontrib>Cho, Yun Ku</creatorcontrib><creatorcontrib>Kim, Yoon Jun</creatorcontrib><creatorcontrib>Yoon, Jung-Hwan</creatorcontrib><creatorcontrib>Kim, Hyo-Cheol</creatorcontrib><creatorcontrib>Jae, Hwan Jun</creatorcontrib><title>Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors</title><title>Cardiovascular and interventional radiology</title><addtitle>Cardiovasc Intervent Radiol</addtitle><addtitle>Cardiovasc Intervent Radiol</addtitle><description>Purpose
To assess the safety and effectiveness of transarterial chemoembolization (TACE) of patients who have hepatocellular carcinomas (HCCs) with central bile duct invasion.
Materials and Methods
The institutional review board approved this retrospective study and waived informed consent. Fifty-three patients, initially treated with TACE for HCCs with central bile duct invasion from January 1999 to September 2012, were included. Clinical, laboratory, and survival data were reviewed. Complications and hospitalization length were evaluated using the
χ
2
test, Fisher’s exact test, and logistic regression analysis. Survival was analyzed using the Kaplan–Meier method with log-rank test and Cox proportional hazard model.
Results
Seven patients experienced TACE-related major complications (severe post-embolization syndrome in 3, non-fatal sepsis in 3, and secondary bacterial peritonitis in 1). The overall major complication rate was 13.2 %, but there were no permanent adverse sequelae or deaths within 30 days. Serum total bilirubin ≥3.0 mg/dL was the only significant risk factor for long hospitalization [hazard ratio (HR) = 4.341,
p
= .022]. The median survival was 12.2 months. Extrahepatic metastasis (HR = 6.145,
p
< .001), international normalized ratio (PT-INR) ≥1.20 (HR = 4.564,
p
< .001), vascular invasion (HR = 3.484,
p
= .001), and intermediate tumor enhancement (HR = 2.417,
p
= .019) were significantly associated with shorter survival.
Conclusion
TACE can be a safe and effective treatment for patients who have HCCs with central bile duct invasion. In particular, long-term survival can be expected if patients have strongly enhancing tumors without poor prognostic factors such as extrahepatic metastasis, PT-INR prolongation, and vascular invasion.</description><subject>Aged</subject><subject>Bile Ducts - pathology</subject><subject>BILIARY TRACT</subject><subject>BILIRUBIN</subject><subject>Carcinoma, Hepatocellular - diagnostic imaging</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Cardiology</subject><subject>Chemoembolization, Therapeutic</subject><subject>Clinical Investigation</subject><subject>DEATH</subject><subject>Female</subject><subject>HAZARDS</subject><subject>HEPATOMAS</subject><subject>Humans</subject><subject>Imaging</subject><subject>Kaplan-Meier Estimate</subject><subject>Length of Stay - statistics & numerical data</subject><subject>Liver Neoplasms - diagnostic imaging</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>METASTASES</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Nuclear Medicine</subject><subject>PATIENTS</subject><subject>PERITONITIS</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>REGRESSION ANALYSIS</subject><subject>Retrospective Studies</subject><subject>REVIEWS</subject><subject>Survival Rate</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>Ultrasound</subject><subject>VASCULAR DISEASES</subject><subject>WHO</subject><issn>0174-1551</issn><issn>1432-086X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kcFu1TAQRS0Eoq-FD2CDLLFh0YDt2E7CDlJKK1UCiSKxsxxn3OcqsV9tp6h8AZ-Nn1IKG1Yea869o5mL0AtK3lBCmreJENaQilBeUVKzqnuENpSXgrTy-2O0IbQpHSHoATpM6ZoQKlomnqIDJrgURIoN-nUZtU86ZohOT7jfwhxgHsLkfursgsc2RHwGO52DgWlaJh1xr6NxPsw64R8ub3EPPsci_uAmwCeLyfjc3-pU1O_wV20h3x3jLzFc-ZBcOsbaj-ULozPZ3QI-1SaHmJ6hJ1ZPCZ7fv0fo2-nHy_6suvj86bx_f1EZ3pBcdbZmNZSV9CAZsaOgw1hTwtlgbcvoQAh0RnS2sVJCM7SDJdJIDu3IeWeHtj5Cr1bfkLJTybgMZmuC92CyYozLrm14oV6v1C6GmwVSVrNL-wNoD2FJispOypZx0f01fECvwxJ92WFPiU7UvG0KRVfKxJBSBKt20c063ilK1D5MtYapSphqH6baO7-8d16GGcYHxZ_0CsBWIJWWv4L4z-j_uv4GZrqqvQ</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Choi, Jin Woo</creator><creator>Chung, Jin Wook</creator><creator>Cho, Yun Ku</creator><creator>Kim, Yoon Jun</creator><creator>Yoon, Jung-Hwan</creator><creator>Kim, Hyo-Cheol</creator><creator>Jae, Hwan Jun</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20150801</creationdate><title>Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors</title><author>Choi, Jin Woo ; Chung, Jin Wook ; Cho, Yun Ku ; Kim, Yoon Jun ; Yoon, Jung-Hwan ; Kim, Hyo-Cheol ; Jae, Hwan Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-9f323e551ab620fd51bd31042bff821b00e9c59f7f66e7b8bf06c64e8d449fb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Bile Ducts - pathology</topic><topic>BILIARY TRACT</topic><topic>BILIRUBIN</topic><topic>Carcinoma, Hepatocellular - diagnostic imaging</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Cardiology</topic><topic>Chemoembolization, Therapeutic</topic><topic>Clinical Investigation</topic><topic>DEATH</topic><topic>Female</topic><topic>HAZARDS</topic><topic>HEPATOMAS</topic><topic>Humans</topic><topic>Imaging</topic><topic>Kaplan-Meier Estimate</topic><topic>Length of Stay - statistics & numerical data</topic><topic>Liver Neoplasms - diagnostic imaging</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>METASTASES</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Nuclear Medicine</topic><topic>PATIENTS</topic><topic>PERITONITIS</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>REGRESSION ANALYSIS</topic><topic>Retrospective Studies</topic><topic>REVIEWS</topic><topic>Survival Rate</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>Ultrasound</topic><topic>VASCULAR DISEASES</topic><topic>WHO</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Jin Woo</creatorcontrib><creatorcontrib>Chung, Jin Wook</creatorcontrib><creatorcontrib>Cho, Yun Ku</creatorcontrib><creatorcontrib>Kim, Yoon Jun</creatorcontrib><creatorcontrib>Yoon, Jung-Hwan</creatorcontrib><creatorcontrib>Kim, Hyo-Cheol</creatorcontrib><creatorcontrib>Jae, Hwan Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Cardiovascular and interventional radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Jin Woo</au><au>Chung, Jin Wook</au><au>Cho, Yun Ku</au><au>Kim, Yoon Jun</au><au>Yoon, Jung-Hwan</au><au>Kim, Hyo-Cheol</au><au>Jae, Hwan Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors</atitle><jtitle>Cardiovascular and interventional radiology</jtitle><stitle>Cardiovasc Intervent Radiol</stitle><addtitle>Cardiovasc Intervent Radiol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>38</volume><issue>4</issue><spage>937</spage><epage>945</epage><pages>937-945</pages><issn>0174-1551</issn><eissn>1432-086X</eissn><abstract>Purpose
To assess the safety and effectiveness of transarterial chemoembolization (TACE) of patients who have hepatocellular carcinomas (HCCs) with central bile duct invasion.
Materials and Methods
The institutional review board approved this retrospective study and waived informed consent. Fifty-three patients, initially treated with TACE for HCCs with central bile duct invasion from January 1999 to September 2012, were included. Clinical, laboratory, and survival data were reviewed. Complications and hospitalization length were evaluated using the
χ
2
test, Fisher’s exact test, and logistic regression analysis. Survival was analyzed using the Kaplan–Meier method with log-rank test and Cox proportional hazard model.
Results
Seven patients experienced TACE-related major complications (severe post-embolization syndrome in 3, non-fatal sepsis in 3, and secondary bacterial peritonitis in 1). The overall major complication rate was 13.2 %, but there were no permanent adverse sequelae or deaths within 30 days. Serum total bilirubin ≥3.0 mg/dL was the only significant risk factor for long hospitalization [hazard ratio (HR) = 4.341,
p
= .022]. The median survival was 12.2 months. Extrahepatic metastasis (HR = 6.145,
p
< .001), international normalized ratio (PT-INR) ≥1.20 (HR = 4.564,
p
< .001), vascular invasion (HR = 3.484,
p
= .001), and intermediate tumor enhancement (HR = 2.417,
p
= .019) were significantly associated with shorter survival.
Conclusion
TACE can be a safe and effective treatment for patients who have HCCs with central bile duct invasion. In particular, long-term survival can be expected if patients have strongly enhancing tumors without poor prognostic factors such as extrahepatic metastasis, PT-INR prolongation, and vascular invasion.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25465065</pmid><doi>10.1007/s00270-014-1032-9</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0174-1551 |
| ispartof | Cardiovascular and interventional radiology, 2015-08, Vol.38 (4), p.937-945 |
| issn | 0174-1551 1432-086X |
| language | eng |
| recordid | cdi_osti_scitechconnect_22469874 |
| source | MEDLINE; Springer Online Journals Complete |
| subjects | Aged Bile Ducts - pathology BILIARY TRACT BILIRUBIN Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Cardiology Chemoembolization, Therapeutic Clinical Investigation DEATH Female HAZARDS HEPATOMAS Humans Imaging Kaplan-Meier Estimate Length of Stay - statistics & numerical data Liver Neoplasms - diagnostic imaging Liver Neoplasms - pathology Liver Neoplasms - therapy Male Medicine Medicine & Public Health METASTASES Middle Aged Neoplasm Invasiveness Nuclear Medicine PATIENTS PERITONITIS Prognosis Proportional Hazards Models Radiology RADIOLOGY AND NUCLEAR MEDICINE REGRESSION ANALYSIS Retrospective Studies REVIEWS Survival Rate Tomography, X-Ray Computed Treatment Outcome Ultrasound VASCULAR DISEASES WHO |
| title | Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T17%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transarterial%20Chemoembolization%20for%20Hepatocellular%20Carcinomas%20with%20Central%20Bile%20Duct%20Invasion:%20Safety,%20Prognosis,%20and%20Predictive%20Factors&rft.jtitle=Cardiovascular%20and%20interventional%20radiology&rft.au=Choi,%20Jin%20Woo&rft.date=2015-08-01&rft.volume=38&rft.issue=4&rft.spage=937&rft.epage=945&rft.pages=937-945&rft.issn=0174-1551&rft.eissn=1432-086X&rft_id=info:doi/10.1007/s00270-014-1032-9&rft_dat=%3Cproquest_osti_%3E3742045661%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1695953487&rft_id=info:pmid/25465065&rfr_iscdi=true |